Akari Therapeutics Collaborates with Whitehawk Therapeutics to Expand ADC Payload Platform Potential

This is sponsored content.  Barchart is not endorsing the websites or products set forth below.

Akari Therapeutics (NASDAQ: AKTX) continues to execute on its strategy of advancing a differentiated payload platform designed for the next generation of antibody drug conjugates (ADCs). The Company's newly announced strategic research collaboration with Whitehawk Therapeutics represents another important step in evaluating the broader potential of its proprietary PH1 RNA splice modulating payload technology.

The collaboration will validate the concept of combining Akari’s PH1 payload with Whitehawk’s TOP1 payload to drive synergistic and breakthrough efficacy in preclinical cancer models and support the exploration of new ADC product candidates using this dual-payload technology.

Expanding the Potential of PH1

Since introducing PH1, Akari has consistently positioned the technology as more than a payload for AKTX-101.

The Company believes PH1 represents a differentiated payload class that may have applications across multiple novel ADC molecules and products.

The Whitehawk collaboration is designed to evaluate that opportunity by exploring whether PH1 can work synergistically with the most dominant ADC payload class used in both approved ADCs and those in development today.

The planned studies will assess synergies between the two payloads while generating data intended to guide future development decisions between the two companies.

Building Upon Existing Momentum

The announcement follows a series of milestones supporting Akari's PH1 platform.

The Company continues to advance AKTX-101 through IND-enabling studies while expanding research collaborations that evaluate additional applications for its proprietary payload technology.

Each collaboration provides another opportunity to generate data supporting PH1's differentiated mechanism and ADC platform potential.

According to President and Chief Executive Officer Abizer Gaslightwala, the collaboration is intended to explore the broader potential of PH1 to combine in unique ways with current classes of ADC payloads and advance innovation for cancer patients.

Why It Matters

The ADC field continues to evolve as companies seek new ways to improve therapeutic performance.

While most current ADCs rely on a single payload, Akari and Whitehawk are evaluating whether combining differentiated payload technologies may create future opportunities for improved cancer therapies.

If successful, the collaboration could further demonstrate the power of PH1 while supporting additional development opportunities beyond Akari's internal ADC pipeline.

As Akari continues advancing AKTX-101 toward the clinic, strategic collaborations such as this may provide additional validation for the Company's proprietary payload platform and reinforce its long-term ADC payload strategy.

The above is sponsored content. Barchart was paid up to twenty seven thousand four hundred ninety eight dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of July 2026.  For more information please view the Barchart Disclosure Policy here.